Forneris M, Gottardo L, Albertin G, Malendowicz L K, Nussdorfer G G
Department of Human Anatomy and Physiology, Section of Anatomy, University of Padua, I-35121 Padua, Italy.
Int J Mol Med. 2001 Dec;8(6):675-9. doi: 10.3892/ijmm.8.6.675.
Adrenomedullin (ADM) is a hypotensive peptide, that derives from the proteolytic cleavage of pro(p)ADM and acts through two subtypes of receptors, called L1-receptor (L1-R) and calcitonin receptor-like receptor (CRLR). CRLR may function as a calcitonin gene-related peptide or a selective ADM receptor depending on the expression of the subtype 1 or the subtypes 2 and 3 of a family of proteins, named receptor-activity modifying proteins (RAMPs). Reverse transcription (RT)-polymerase chain reaction (PCR) allowed the detection of pADM mRNA in dispersed cells of eight Conn's adenomas (aldosteronomas). These cells also expressed peptidyl-glycine alpha-amidating monooxigenase, the enzyme converting immature ADM to the mature form, and contained sizeable amounts of ADM-immunoreactivity as measured by radioimmunoassay. RT-PCR also demonstrated the presence in aldosteronoma cells of the specific mRNAs of L1-R, CRLR and RAMPs 1-3. ADM (10(-8) M) inhibited angiotensin-II (10(-9) M)-simulated aldosterone secretion from cultured aldosteronoma cells, without affecting basal production. ADM (10(-8) M) also enhanced basal proliferation rate of cultured cells, as estimated by the 5-bromo-2'-deoxyuridine immunocytochemical technique. Both effects of ADM were annulled by the ADM-receptor selective antagonist ADM22-52 (10(-7) M). In conclusion, our study provides evidence that aldosteronoma cells express both ADM and ADM22-52-sensitive receptors. These findings, coupled with the demonstration that ADM exerts an aldosterone antisecretagogue action and a proliferogenic effect on cultured aldosteronoma cells, make it likely that endogenous ADM system plays a potentially important role in the paracrine or autocrine functional control of Conn's adenomas.
肾上腺髓质素(ADM)是一种降压肽,它由前体(p)ADM经蛋白水解切割产生,并通过两种受体亚型发挥作用,即L1受体(L1-R)和降钙素受体样受体(CRLR)。CRLR可作为降钙素基因相关肽或选择性ADM受体发挥作用,这取决于一种名为受体活性修饰蛋白(RAMP)家族的1型亚型或2型和3型亚型的表达情况。逆转录(RT)-聚合酶链反应(PCR)可检测出8例Conn腺瘤(醛固酮瘤)分散细胞中的pADM mRNA。这些细胞还表达肽基甘氨酸α-酰胺化单加氧酶,该酶可将未成熟的ADM转化为成熟形式,并且通过放射免疫测定法测量发现含有相当数量的ADM免疫反应性物质。RT-PCR还证实醛固酮瘤细胞中存在L1-R、CRLR和RAMP 1-3的特异性mRNA。ADM(10⁻⁸ M)可抑制血管紧张素II(10⁻⁹ M)刺激培养的醛固酮瘤细胞分泌醛固酮,且不影响基础分泌量。ADM(10⁻⁸ M)还可通过5-溴-2'-脱氧尿苷免疫细胞化学技术评估,提高培养细胞的基础增殖率。ADM的这两种作用均被ADM受体选择性拮抗剂ADM22-52(10⁻⁷ M)消除。总之,我们的研究提供了证据表明醛固酮瘤细胞同时表达ADM和对ADM22-52敏感的受体。这些发现,再加上ADM对培养的醛固酮瘤细胞具有醛固酮分泌抑制作用和增殖作用的证明,使得内源性ADM系统很可能在Conn腺瘤的旁分泌或自分泌功能控制中发挥潜在的重要作用。